HCV Hepatitis C virus
Conditions
Interventions
The subjects will receive the study drugs, under direct observation, on Day 1
of each period according to the four-treatment, four-period,
four-sequence randomization schedule. Each treatment will be
Sponsors
Merck Sharp & Dohme (MSD)
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1. Non-tobacco using males and females, 18-55 years of age, inclusive. 2. A body mass index (BMI) of 19-32 kg/m² inclusive as calculated according to QPS Netherlands B.V. Standard Operating Procedures. 3. Good health as determined by lack of clinically significant abnormalities in health assessments performed at screening.
Exclusion criteria
Exclusion criteria: 1. Females who are pregnant, lactating or intend to become pregnant during the study. 2. History of allergy or sensitivity to MK-3682, MK-5172, or MK-8742 or history of any drug hypersensitivity or intolerance which, in the opinion of the Investigator, would compromise the safety of the subject or the integrity of study. 3. Significant history or current evidence of chronic infectious disease, system disorders, organ dysfunction, especially cardiovascular disorders (angina, heart failure, irregular heartbeats, heart attack, hypertension, hypotension), stroke, renal or hepatic disorder, diabetes or bleeding 4. Receipt of any drug as part of a research study within 30 days before initial dosing.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hypothesis (Estimation): To estimate the comparative bioavailability of each of the three test PMFs of an FDC of MK-3682A (FDC-F, FDC-G, and FDC-H) relative to the reference PMF of MK-3682A FDC (FDC-E) following single-dose administration. | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety | — |
Countries
Netherlands
Outcome results
None listed